Fight Flu Season with Vivalytic
Fight Flu Season with Vivalytic!
As we enter the Winter 2024/25 flu season, healthcare providers and patients face the co-circulation of influenza, RSV, and SARS-CoV-2. This combination of respiratory pathogens presents unique challenges, particularly for vulnerable groups, and highlights the critical need for rapid, accurate diagnostics. Vaccination among frontline healthcare workers remains essential to reduce transmission, protect high-risk patients, and prevent staff shortages in healthcare facilities.
The Seasonal Threat of Respiratory Infections
Every year, influenza outbreaks affect millions globally, especially during winter. In England, 2023/2024 saw 2,776 flu-related deaths, highlighting the burden on healthcare systems. Vulnerable groups, including older adults, pregnant women, and those with chronic conditions, face heightened risks of severe outcomes like pneumonia or ICU admissions.
Pamela Rendi-Wagner, Director of the European Centre for Disease Prevention and Control, stressed that “vaccination is one of the most effective measures to protect vulnerable populations from severe disease, hospitalisation, and death.” Recent data shows significant variability in flu vaccination rates among older adults, ranging from 12% to 78% across Europe, with only two countries exceeding 75% coverage.
Vaccination remains the cornerstone of flu prevention for high-risk groups like the elderly, immunocompromised, and healthcare workers. However, diagnostic testing plays an equally vital role this flu season. Rapid and accurate testing prevents unnecessary hospitalisations, reduces severe outcomes in vulnerable populations, and ensures effective use of healthcare resources.
Enter Vivalytic
Accurate and rapid diagnosis is essential for effective treatment and control of respiratory infections, especially during flu season. By identifying the specific pathogen, healthcare providers can tailor treatment plans, combat anti-microbial resistance, reduce the spread within communities, and alleviate pressure on healthcare systems.
Enter Vivalytic; and with it the SARS, Flu A/B, and RSV Panel, offering an all-in-one solution for simultaneous testing of key respiratory pathogens. This panel ensures that healthcare professionals can diagnose and differentiate between influenza, RSV, and SARS-CoV-2 swiftly, providing crucial information to guide patient management.
Features of the Vivalytic SARS, Flu A/B and RSV Panel
- All-in-One Solution: Multi-pathogen testing with a single cartridge, eliminating the need for complex manual preparation.
- Rapid Results: With a turnaround time of just 53 minutes, the Vivalytic Flu panel enables swift decision-making, crucial in time-sensitive cases from a single nasopharyngeal or oropharyngeal swab sample.
- User-Friendly Design: An intuitive touchscreen interface requires minimal training, making it ideal for use in a variety of healthcare settings, including those with non-specialist operators.
| Detectable Pathogens |
|---|
| SARS-CoV-2 (E gene & N gene) |
| Influenza A and Influenza B |
| Human Respiratory Syncytial Virus |
Meeting the Challenges of the 2024/2025 Flu Season
As flu season progresses, the need for efficient and reliable diagnostics becomes ever more apparent. Fight Flu Season with Vivalytic, the SARS, Flu A/B, and RSV Panel is not only a valuable tool for diagnosing individual cases but also plays a critical role in protecting public health by enabling rapid response and management of outbreaks.
Learn more about the Vivalytic, with one of the largest test menus on the market and how it can support your testing needs this winter here: Vivalytic | Point of Care | Randox Laboratories
Contact marketing@randox.com for more information